Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Fortem Financial Group LLC

Share on StockTwits

Fortem Financial Group LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 63.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,326 shares of the medical research company’s stock after selling 2,256 shares during the quarter. Fortem Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of TMO. Two Sigma Advisers LP bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $22,773,000. Maverick Capital Ltd. bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $63,000. APG Asset Management N.V. lifted its position in Thermo Fisher Scientific by 11.3% in the 1st quarter. APG Asset Management N.V. now owns 359,073 shares of the medical research company’s stock valued at $101,833,000 after purchasing an additional 36,357 shares during the last quarter. Procyon Private Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 13.4% in the 1st quarter. Procyon Private Wealth Partners LLC now owns 1,217 shares of the medical research company’s stock valued at $345,000 after purchasing an additional 144 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in Thermo Fisher Scientific by 2.0% in the 1st quarter. Schroder Investment Management Group now owns 873,670 shares of the medical research company’s stock valued at $265,595,000 after purchasing an additional 16,711 shares during the last quarter. Hedge funds and other institutional investors own 88.12% of the company’s stock.

Several analysts recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $352.00 to $436.00 in a research report on Thursday, July 23rd. Cowen restated a “buy” rating and set a $380.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. BTIG Research boosted their price target on shares of Thermo Fisher Scientific from $372.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, July 23rd. Citigroup boosted their price target on shares of Thermo Fisher Scientific from $471.00 to $485.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Finally, Atlantic Securities assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 30th. They set an “overweight” rating and a $494.00 price target on the stock. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $452.27.

NYSE:TMO traded up $4.03 during trading hours on Friday, hitting $468.59. 1,070,263 shares of the company traded hands, compared to its average volume of 1,656,574. The stock has a market capitalization of $185.37 billion, a price-to-earnings ratio of 50.71, a P/E/G ratio of 1.88 and a beta of 1.01. Thermo Fisher Scientific Inc. has a twelve month low of $250.21 and a twelve month high of $473.84. The firm has a 50-day moving average of $433.77 and a 200 day moving average of $378.29. The company has a current ratio of 2.62, a quick ratio of 2.02 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.22. The firm had revenue of $6.92 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Thermo Fisher Scientific had a net margin of 14.12% and a return on equity of 18.18%. During the same period in the prior year, the company earned $3.04 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 15.27 earnings per share for the current fiscal year.

In related news, COO Mark Stevenson sold 22,000 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $420.16, for a total transaction of $9,243,520.00. Following the completion of the transaction, the chief operating officer now directly owns 34,561 shares in the company, valued at approximately $14,521,149.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jim P. Manzi sold 3,218 shares of the business’s stock in a transaction on Friday, July 24th. The shares were sold at an average price of $402.38, for a total transaction of $1,294,858.84. Following the completion of the sale, the director now directly owns 21,803 shares in the company, valued at approximately $8,773,091.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,868 shares of company stock valued at $71,253,379. Corporate insiders own 0.44% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Read More: Why do companies engage in swaps?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.